Product Images Pemetrexed

This is a chart showing survival probability for patients receiving treatment with Pemetrexed + Cisplatin compared to those receiving Cisplatin alone. The x-axis represents survival time in months while the y-axis shows the patients at risk. The data seems to be incomplete and further information cannot be determined from it.*

This is a description of a medication labeled LOT/EXP print area. The medication is Pemetrexed Injection, containing 10mg pemetrexed disodium hemipentahydrate (equivalent to 12.1mg of pemetrexed) per mL; it has a dosage of 10mg/mL. The drug is intended for intravenous infusion only and is packaged as a single-dose vial. Any unused portion should be discarded. The medication should be administered undiluted and stored at room temperature in the range of 59°F to 86°F. The medication is hazardous, and the manufacturer is Shilpa Medicare Limited in Jadcherla-509301, India. The LOT/EXP format is YYYY-MM.*

This is a pharmaceutical label providing information on a medication called Pemetrexed. It contains details such as the GTIN, LOT, and EXP, which are used for tracking and tracing purposes. There is also information on the concentration of the medication and how it should be administered. Additionally, the label indicates that variable data and a 2D data matrix are printed during packing in an unvarnished Arez material.*

This is a pharmaceutical label for a Pemetrexed Injection, with a concentration of 10 mg/mL, designed for intravenous infusion. The recommended dosage is 500 mg/50 ml. The product is produced by BVF Inc. and has a GTIN code of XX000000000K. There is additional information on the label regarding storage conditions and administration instructions.*

This is a description of Pemetrexed Injection, a hazardous drug for intravenous infusion only. The drug comes in a single-use vial, and the recommended dosage should be determined by a doctor. Each mL of the injection contains 10 mg of pemetrexed. The NDC number for this drug is 63759-3050-1, and it is manufactured by Zydus Lifesciences Limited in Ahmedabad, India, for Shilpa Medicare Limited in Jadcherla, India. The drug should be stored at a temperature between 20°C and 25°C. The lot number for this injection is XXK000KK. The text also includes other information such as the hazardous nature of the drug, the GTIN code, and the required storage conditions.*

The text seems to be a table about the number of patients and their survival probability under Pemetrexed and Placebo treatment. The table includes information about patients at risk and their survival time in months. However, several characters are not readable, making it challenging to understand the full context.*

This is a survival analysis table describing the number of patients at risk and their survival probability. The table shows the number of patients who received Pometrexed and Placebo, respectively, and the number of months they survived. The values in the second row are not clear, so the information is not available.*

This appears to be a chart or graph showing the "Survival Probability" of two groups of patients receiving either "pemetroxed" or a placebo. The chart also includes the number of patients "at risk" in each group at various time intervals, as well as the time interval in months. However, the output is not readable in some parts and the meaning of certain symbols is unclear, so it is difficult to provide a more detailed description.*

This appears to be a table showing survival probability and time (in months) for two different treatments - pemetrexed and placebo. The table also shows the number of individuals who were still at risk for each time point. Not much additional context can be determined from the given text.*